Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 12/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.49 |
| ▸ | STK17B | O94768 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253012 | 1.00 | BCL6 (0.66) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL3494580 | 0.87 | BCL6 (0.86) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL13273838 | 0.87 | BCL6 (0.49) | BCL6SYKEGFR | |
| SCHEMBL2103262 | 0.86 | BCL6 (0.80) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL3495051 | 0.83 | BCL6 (0.63) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL3495768 | 0.82 | BCL6 (0.69) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL3497111 | 0.81 | BCL6 (0.61) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL655635 | 0.81 | BCL6 (0.80) | BCL6NCOR2SYKSTK17BSTK17A | |
| SCHEMBL3494019 | 0.80 | BCL6 (0.62) | BCL6NCOR2SYKULK1ULK2 | |
| SCHEMBL3496329 | 0.80 | BCL6 (0.64) | BCL6NCOR2SYKULK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387565-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8334297-B2 | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | RIGEL PHARMACEUTICALS INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2387565-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8038847-B2 | Structured forming fabric, papermaking machine and method | VOITH PATENT GMBH (DE) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083241-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | IL2, IL1B, IL1A | BCL6 701/4885NCOR2 3257/4885SYK 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.